ResearcherJohns Hopkins UniversityActive in the last 2 years
Matthew Z. Guo
Matched on ORCID iD 0000-0003-4741-7463; OpenAlex author ID A5012455959. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 36
2025: 2 papers · 2026: 2 papers
Papers 4
- Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
- First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
- Emerging Systemic Therapy Considerations for Pancreatic Cancer. First author DOI 10.1016/j.semradonc.2025.07.006↗
- A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… First author DOI 10.1158/1078-0432.ccr-24-3403↗
Closest collaborators
The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elizabeth M. Jaffee · 3 shared papers, 2025–2026 · strength 0.65
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Daniel A. Laheru · 3 shared papers, 2025–2026 · strength 0.65
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Neeha Zaidi · 2 shared papers, 2025–2026 · strength 0.63
- Katherine M. Bever · 2 shared papers, 2026 · strength 0.46
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Richard Andrew Burkhart · 2 shared papers, 2025–2026 · strength 0.44
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359↗
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Kai-li Liang · 1 shared paper, 2025 · strength 0.42
- Hao Wang · 2 shared papers, 2025–2026 · strength 0.40
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Mark M. Yarchoan · 2 shared papers, 2025–2026 · strength 0.40
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borde… DOI 10.1158/1078-0432.ccr-24-3403↗
- Eric Scott Christenson · 1 shared paper, 2026 · strength 0.25
- William Reece Burns · 1 shared paper, 2026 · strength 0.25
- Dung Thi Le · 1 shared paper, 2026 · strength 0.25
- Jin He · 1 shared paper, 2026 · strength 0.25
- Christopher R. Shubert · 1 shared paper, 2026 · strength 0.25
- Sagar D. Patel · 1 shared paper, 2026 · strength 0.25
- Kelly J. Lafaro · 1 shared paper, 2026 · strength 0.25
- Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.25
- Dimitrios N. Sidiropoulos · 1 shared paper, 2026 · strength 0.21
- Saurav Daniel Haldar · 1 shared paper, 2026 · strength 0.21
- Marina Baretti · 1 shared paper, 2026 · strength 0.21
- Takeichi Yoshida · 1 shared paper, 2026 · strength 0.21
- Luciane Tsukamoto Kagohara · 1 shared paper, 2026 · strength 0.21
- Hassan Sinan · 1 shared paper, 2026 · strength 0.21
- Elizabeth Abou Diwan · 1 shared paper, 2026 · strength 0.21
- Nilofer Saba Azad · 1 shared paper, 2026 · strength 0.21
- Michael Goggins · 1 shared paper, 2026 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.